

# Matteo Landriscina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7464230/publications.pdf>

Version: 2024-02-01

109  
papers

4,389  
citations

101543

36  
h-index

118850

62  
g-index

111  
all docs

111  
docs citations

111  
times ranked

5713  
citing authors

#	ARTICLE	IF	CITATIONS
1	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. <i>Biomedicines</i> , 2022, 10, 236.	3.2	13
2	The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs. <i>Panminerva Medica</i> , 2022, 64, .	0.8	7
3	Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines. <i>Oncology Letters</i> , 2022, 23, 185.	1.8	0
4	TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	4
5	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7844.	4.1	3
6	Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas. <i>Cancers</i> , 2021, 13, 158.	3.7	16
7	Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-5.	1.3	10
8	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7717.	4.1	7
9	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12330.	4.1	16
10	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. <i>Cells</i> , 2021, 10, 3166.	4.1	20
11	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. <i>Cells</i> , 2021, 10, 3165.	4.1	9
12	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). <i>International Journal of Molecular Sciences</i> , 2021, 22, 12297.	4.1	10
13	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12314.	4.1	6
14	Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?. <i>Molecular and Cellular Endocrinology</i> , 2020, 502, 110676.	3.2	5
15	Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 145.	4.1	3
16	TRAP1 Regulates Wnt/ $\beta$ -Catenin Pathway through LRP5/6 Receptors Expression Modulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7526.	4.1	6
17	TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. <i>Molecular Oncology</i> , 2020, 14, 3030-3047.	4.6	19
18	IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives. <i>Molecules</i> , 2020, 25, 3754.	3.8	18

#	ARTICLE	IF	CITATIONS
19	Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer. <i>Biomolecules</i> , 2020, 10, 135.	4.0	43
20	Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer. <i>Cells</i> , 2020, 9, 828.	4.1	41
21	Heat shock proteins in cancer stem cell maintenance: A potential therapeutic target?. <i>Histology and Histopathology</i> , 2020, 35, 25-37.	0.7	4
22	Metabolic Dysregulations and Epigenetics: A Bidirectional Interplay that Drives Tumor Progression. <i>Cells</i> , 2019, 8, 798.	4.1	31
23	BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. <i>Cancers</i> , 2019, 11, 1388.	3.7	73
24	HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy. <i>Cells</i> , 2019, 8, 532.	4.1	68
25	Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance between Apoptosis and Autophagy and Its Role in Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2019, 20, 857.	4.1	113
26	Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells. <i>Tumor Biology</i> , 2018, 40, 101042831877095.	1.8	7
27	Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. <i>Medical Oncology</i> , 2018, 35, 28.	2.5	14
28	Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review. <i>Urologia Internationalis</i> , 2018, 101, 125-131.	1.3	21
29	Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2114-S2118.	1.4	4
30	Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation. <i>Nucleic Acids Research</i> , 2018, 46, 12067-12086.	14.5	20
31	New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2289-2293.	2.2	16
32	IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. <i>Cancer Letters</i> , 2018, 433, 147-155.	7.2	27
33	TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor. <i>Genes</i> , 2018, 9, 195.	2.4	65
34	TRAP1. , 2018, , 5680-5690.		0
35	Stress-Adaptive Response in Ovarian Cancer Drug Resistance. <i>Advances in Protein Chemistry and Structural Biology</i> , 2017, 108, 163-198.	2.3	34
36	TRAP1 controls cell cycle G2â€M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. <i>Journal of Pathology</i> , 2017, 243, 123-134.	4.5	34

#	ARTICLE	IF	CITATIONS
37	TRAP1: a viable therapeutic target for future cancer treatments?. Expert Opinion on Therapeutic Targets, 2017, 21, 805-815.	3.4	30
38	Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell International, 2017, 17, 86.	4.1	28
39	TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. Oncotarget, 2017, 8, 21229-21240.	1.8	18
40	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of <i>IGFBP6</i> . Oncotarget, 2017, 8, 60826-60840.	1.8	21
41	RAD6: a new target to overcome platinum resistance in ovarian cancer?. Translational Cancer Research, 2017, 6, S1476-S1479.	1.0	0
42	TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. Cell Death and Disease, 2016, 7, e2522-e2522.	6.3	40
43	Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death and Differentiation, 2016, 23, 1542-1554.	11.2	154
44	TRAP1 regulates stemness through Wnt/ $\beta$ -catenin pathway in human colorectal carcinoma. Cell Death and Differentiation, 2016, 23, 1792-1803.	11.2	47
45	TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. Endocrine-Related Cancer, 2016, 23, 699-709.	3.1	24
46	DAA's Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS ONE, 2016, 11, e0167934.	2.5	96
47	TRAP1., 2016, , 1-11.		0
48	Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography. Molecular Imaging, 2015, 14, 7290.2015.00021.	1.4	21
49	RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. Oncology Letters, 2015, 10, 1875-1881.	1.8	2
50	TRAP1 controls cell migration of cancer cells in metabolic stress conditions: Correlations with AKT/p70S6K pathways. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2570-2579.	4.1	23
51	The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology, 2015, 867, 159-176.	1.6	28
52	Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: A novel strategy for human BRAF-driven colorectal carcinoma. Oncotarget, 2015, 6, 22298-22309.	1.8	36
53	5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget, 2015, 6, 41706-41721.	1.8	103
54	Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography. Molecular Imaging, 2015, 14, 490-8.	1.4	6

#	ARTICLE	IF	CITATIONS
55	ER stress protection in cancer cells: the multifaceted role of the heat shock protein TRAP1. <i>Endoplasmic Reticulum Stress in Diseases</i> , 2014, 1, .	0.2	1
56	TRAP1 revisited: Novel localizations and functions of a "next-generation" biomarker (Review). <i>International Journal of Oncology</i> , 2014, 45, 969-977.	3.3	50
57	Pyrosequencing evaluation of low-frequency <i>KRAS</i> mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. <i>Future Oncology</i> , 2014, 10, 713-723.	2.4	10
58	TRAP1 Is Involved in BRAF Regulation and Downstream Attenuation of ERK Phosphorylation and Cell-Cycle Progression: A Novel Target for BRAF-Mutated Colorectal Tumors. <i>Cancer Research</i> , 2014, 74, 6693-6704.	0.9	43
59	Validation of Vacuum-Based Refrigerated System for Biobanking Tissue Preservation: Analysis of Cellular Morphology, Protein Stability, and RNA Quality. <i>Biopreservation and Biobanking</i> , 2014, 12, 35-45.	1.0	12
60	The Role of Survivin in Thyroid Tumors: Differences of Expression in Well-Differentiated, Non-Well-Differentiated, and Anaplastic Thyroid Cancers. <i>Thyroid</i> , 2014, 24, 511-519.	4.5	28
61	TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: Relevance in human colorectal tumors. <i>Molecular Oncology</i> , 2014, 8, 1482-1494.	4.6	32
62	TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. <i>International Journal of Oncology</i> , 2014, 44, 573-582.	3.3	27
63	The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase. <i>Cell Metabolism</i> , 2013, 17, 988-999.	16.2	217
64	Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. <i>Molecular Oncology</i> , 2013, 7, 895-906.	4.6	68
65	Multiple Skeletal Muscle Metastases from Colon Carcinoma Preceded by Paraneoplastic Dermatomyositis. <i>Case Reports in Medicine</i> , 2013, 2013, 1-4.	0.7	4
66	Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. <i>Cell Death and Disease</i> , 2013, 4, e851-e851.	6.3	55
67	Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. <i>Oncology Letters</i> , 2013, 5, 975-977.	1.8	9
68	TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. <i>Cell Death and Differentiation</i> , 2012, 19, 592-604.	11.2	82
69	Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E898-E906.	3.6	42
70	Notch Signaling Modulates Hypoxia-Induced Neuroendocrine Differentiation of Human Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2012, 10, 230-238.	3.4	63
71	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. <i>Medical Oncology</i> , 2012, 29, 3198-3201.	2.5	4
72	New insights into TRAP1 pathway. <i>American Journal of Cancer Research</i> , 2012, 2, 235-48.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Epidermal Growth Factor Receptor 1 Expression Is Upregulated in Undifferentiated Thyroid Carcinomas in Humans. <i>Thyroid</i> , 2011, 21, 1227-1234.	4.5	30
74	Sorcini Induces a Drug-Resistant Phenotype in Human Colorectal Cancer by Modulating Ca <sup>2+</sup> Homeostasis. <i>Cancer Research</i> , 2011, 71, 7659-7669.	0.9	78
75	Insulin-resistant conditions: A favorable milieu for aggressive drug-resistant malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2011, 2, 11-2.	1.4	5
76	Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. <i>Gynecologic Oncology</i> , 2010, 117, 177-182.	1.4	83
77	Mitochondrial Chaperone Trap1 and the Calcium Binding Protein Sorcini Interact and Protect Cells against Apoptosis Induced by Antitubercular Agents. <i>Cancer Research</i> , 2010, 70, 6577-6586.	0.9	120
78	S100A13 is a new angiogenic marker in human melanoma. <i>Modern Pathology</i> , 2010, 23, 804-813.	5.5	61
79	Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. <i>Anticancer Research</i> , 2010, 30, 473-80.	1.1	23
80	Targeting Epidermal Growth Factor Receptor 1 Signaling in Human Thyroid-Stimulating Hormone-Independent Thyroid Carcinoma FRO Cells Results in a More Chemosensitive and Less Angiogenic Phenotype. <i>Thyroid</i> , 2009, 19, 629-637.	4.5	11
81	Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. <i>Prostate</i> , 2009, 69, 744-754.	2.3	22
82	Adaptation to Oxidative Stress, Chemoresistance, and Cell Survival. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 2701-2716.	5.4	186
83	TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. <i>Cancer Letters</i> , 2009, 279, 39-46.	7.2	117
84	Protein folding does not prevent the nonclassical export of FGF1 and S100A13. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 350-354.	2.1	10
85	Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear cell carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 2842-2850.	5.1	35
86	Secretion without Golgi. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1327-1343.	2.6	109
87	The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway. <i>Cancer Letters</i> , 2008, 267, 67-74.	7.2	22
88	Nevirapine Toxicity in Non-HIV Cancer Patients. <i>Chemotherapy</i> , 2008, 54, 475-478.	1.6	7
89	Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report. <i>Acta Oncologica</i> , 2008, 47, 1602-1604.	1.8	13
90	Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors. <i>Current Pharmaceutical Design</i> , 2007, 13, 737-747.	1.9	26

#	ARTICLE	IF	CITATIONS
91	Reinduction of Cell Differentiation and <sup>131</sup> I Uptake in a Poorly Differentiated Thyroid Tumor in Response to the Reverse Transcriptase (RT) Inhibitor Nevirapine. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 289-295.	1.0	19
92	The Nrf2 transcription factor contributes to the induction of alpha-class GST isoenzymes in liver of acute cadmium or manganese intoxicated rats: Comparison with the toxic effect on NAD(P)H:quinone reductase. <i>Toxicology</i> , 2007, 237, 24-34.	4.2	45
93	Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine. <i>Lancet Oncology</i> , The, 2006, 7, 877-879.	10.7	17
94	Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. <i>Oncogene</i> , 2005, 24, 3923-3931.	5.9	168
95	Reverse Transcriptase Inhibitors Down-Regulate Cell Proliferation <i>in Vitro</i> and <i>in Vivo</i> and Restore Thyrotropin Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5663-5671.	3.6	77
96	Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 223-228.	1.0	46
97	Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. <i>Oncogene</i> , 2003, 22, 2750-2761.	5.9	105
98	S100A13 mediates the copper-dependent stress-induced release of IL-1 $\beta$ from both human U937 and murine NIH 3T3 cells. <i>Journal of Cell Science</i> , 2003, 116, 2687-2696.	2.0	86
99	The non-classical export routes: FGF1 and IL-1 $\beta$ point the way. <i>Journal of Cell Science</i> , 2003, 116, 4871-4881.	2.0	184
100	Soluble Jagged 1 Represses the Function of Its Transmembrane Form to Induce the Formation of the Src-dependent Chord-like Phenotype. <i>Journal of Biological Chemistry</i> , 2001, 276, 32022-32030.	3.4	113
101	The Comparative Release of FGF1 by Hypoxia and Temperature Stress. <i>Growth Factors</i> , 2001, 18, 277-285.	1.7	49
102	Copper Induces the Assembly of a Multiprotein Aggregate Implicated in the Release of Fibroblast Growth Factor 1 in Response to Stress. <i>Journal of Biological Chemistry</i> , 2001, 276, 25549-25557.	3.4	106
103	The Precursor but Not the Mature Form of IL1 $\beta$ Blocks the Release of FGF1 in Response to Heat Shock. <i>Journal of Biological Chemistry</i> , 2001, 276, 5147-5151.	3.4	37
104	S100A13 Participates in the Release of Fibroblast Growth Factor 1 in Response to Heat Shock <i>in Vitro</i> . <i>Journal of Biological Chemistry</i> , 2001, 276, 22544-22552.	3.4	77
105	Vinorelbine and Alternating Cisplatin and Ifosfamide in the Treatment of Non-Small Cell Lung Cancer. <i>Oncology</i> , 2000, 58, 25-30.	1.9	5
106	Amlexanox Reversibly Inhibits Cell Migration and Proliferation and Induces the Src-dependent Disassembly of Actin Stress Fibers <i>in Vitro</i> . <i>Journal of Biological Chemistry</i> , 2000, 275, 32753-32762.	3.4	33
107	Iron modulation of LPS-induced manganese superoxide dismutase gene expression in rat tissues. <i>FEBS Letters</i> , 1997, 403, 131-135.	2.8	13
108	Diethyldithiocarbamate Treatment Up Regulates Manganese Superoxide Dismutase Gene Expression in Rat Liver. <i>Biochemical and Biophysical Research Communications</i> , 1996, 220, 546-552.	2.1	13

#	ARTICLE	IF	CITATIONS
109	Solitary metastasis from renal cell carcinoma to the choroid plexus: A case illustration and review of the literature. , 0, 13, 227.		0